|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Herceptin
|
|
gptkbp:activities
|
inhibits HE R2 signaling
|
|
gptkbp:appointed_by
|
oncology
injection
|
|
gptkbp:approves
|
gptkb:2006
gptkb:FDA
|
|
gptkbp:aroma
|
420 mg/50 m L
|
|
gptkbp:availability
|
available in many countries
|
|
gptkbp:brand
|
gptkb:Herceptin
|
|
gptkbp:can_be_used_with
|
chemotherapy
|
|
gptkbp:clinical_trial
|
Phase III
ongoing studies
adjuvant therapy
|
|
gptkbp:contraindication
|
hypersensitivity to trastuzumab
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:duration
|
up to 1 year
|
|
gptkbp:education
|
importance of follow-up
|
|
gptkbp:excretion
|
via reticuloendothelial system
|
|
gptkbp:financial_performance
|
high stability
|
|
gptkbp:healthcare
|
gptkb:hospital
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
trastuzumab-dkst
|
|
gptkbp:indication
|
HE R2-positive breast cancer
|
|
gptkbp:ingredients
|
C6460 H9922 N1710 O1984 S44
|
|
gptkbp:interacts_with
|
immune system
may interact with other cancer therapies
|
|
gptkbp:is_monitored_by
|
cardiac function
|
|
gptkbp:is_used_for
|
treatment of breast cancer
|
|
gptkbp:lifespan
|
approximately 28 days
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:marketed_as
|
gptkb:Herceptin
|
|
gptkbp:metabolism
|
proteolytic degradation
|
|
gptkbp:pharmacokinetics
|
antibody-dependent cellular cytotoxicity
complement-dependent cytotoxicity
long half-life
|
|
gptkbp:population
|
adults
|
|
gptkbp:price
|
high cost
|
|
gptkbp:produced_by
|
Chinese hamster ovary cells
|
|
gptkbp:provides_information_on
|
ASCO guidelines
NCCN guidelines
|
|
gptkbp:receives_funding_from
|
pharmaceutical companies
|
|
gptkbp:regulatory_compliance
|
approved in multiple regions
|
|
gptkbp:related_to
|
gptkb:trastuzumab
|
|
gptkbp:research_focus
|
HE R2-positive cancers
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:scholarships
|
available programs
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
headache
nausea
diarrhea
rash
thrombocytopenia
infusion reactions
neutropenia
cardiotoxicity
|
|
gptkbp:social_structure
|
gptkb:Ig_G1
|
|
gptkbp:storage
|
2-8° C
|
|
gptkbp:targets
|
HE R2 protein
|
|
gptkbp:treatment
|
improved survival rates
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:type_of_insurance
|
varies by plan
|
|
gptkbp:weight
|
146 k Da
|